Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.
The purchase sets up another showdown with the group’s old rival, Bristol Myers Squibb, in LSD1 inhibition.
Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.
The speciality group will soon be without biosimilars; in the meantime it's buying two companies with patent-protected medicines.
Buying Abiomed for $17bn sharpens the group’s focus, somewhat unexpectedly, on cardiovascular tech.
The $2.6bn acquisition of The Binding Site is 2022’s biggest medtech deal, but investors are unmoved.